Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99821 | 1.00 | MTNR1A (0.41) | MTNR1AMTNR1BCYP4F2CYP4A11KCNA3 | |
| SCHEMBL101029 | 0.83 | NR1H4 (0.44) | NR1H2BACE1SMN1; SMN2MAPT | |
| SCHEMBL101030 | 0.83 | NR1H4 (0.44) | NR1H2BACE1SMN1; SMN2MAPT | |
| SCHEMBL16868418 | 0.82 | PAM (0.56) | KCNA3BACE1PAMGRIK1GRIK2 | |
| SCHEMBL16868417 | 0.82 | PAM (0.56) | KCNA3BACE1PAMGRIK1GRIK2 | |
| SCHEMBL28466214 | 0.79 | PAM (0.58) | CYP4F2CYP4A11PAM | |
| SCHEMBL99876 | 0.78 | TDP1 (0.43) | KCNA3SMN1; SMN2 | |
| SCHEMBL99877 | 0.78 | TDP1 (0.43) | KCNA3SMN1; SMN2 | |
| SCHEMBL14472705 | 0.76 | CYP4F2 (0.46) | CYP4F2CYP4A11NR1H2PAMSMN1; SMN2 | |
| SCHEMBL28797524 | 0.76 | CYP4F2 (0.46) | CYP4F2CYP4A11NR1H2PAMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | MTNR1A 430/4885MTNR1B 272/4885CYP4F2 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.